GOS and the Management of Hyperuricemia

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2024
Hyperuricemia is a major risk factor for many chronic diesease. Recently, gut mcirobiota has been identified as a novel therapeutic target for hyperuricemia. Both annimal studies and pilot human trials have demonstrated that administration of prebiotics help delay the progression of hyperuricemia throuh several mechanisms. This trial aims to examine the protective effects and potential mechanisms of galactooligosaccharide on hyperuricemia in clinical trials.
Epistemonikos ID: 8c0a027808f2caf8ad2390002d2928212ac9d39e
First added on: Apr 17, 2025